Page 35 - TD-3-4
P. 35

Tumor Discovery                                                        Expert consensus of NUT carcinoma



               doi: 10.1016/j.jtho.2023.12.022                 81.  Gov. C.  Open Label, Multi-center Study to Assess the Safety,
                                                                  Tolerability and Pharmacokinetics of CUDC-907 in Subjects
            72.  Storck S, Kennedy AL, Marcus KJ,  et al. Pediatric NUT-  With Advanced Relapsed Solid Tumors [EB/OL]; 2019. Available
               midline carcinoma: Therapeutic success employing a   from: https://clinicaltrials.gov/study/nct02307240?cond=cudc-
               sarcoma based multimodal approach.  Pediatr Hematol   907&rank=2 [Last accessed on 2023 Sep 22].
               Oncol. 2017;34(4):231-237.
                                                               82.  Shapiro GI, LoRusso P, Dowlati A, et al. A phase 1 study
               doi: 10.1080/08880018.2017.1363839                 of RO6870810, a novel bromodomain and extra-terminal
            73.  Vorstenbosch LJMJ, Mavinkurve-Groothuis AMC, van   protein inhibitor, in patients with NUT carcinoma, other
               den Broek G, Flucke U, Janssens GO. Long-term survival   solid tumours, or diffuse large B-cell lymphoma. Br J Cancer.
               after relapsed NUT carcinoma of the larynx. Pediatr Blood   2021;124(4):744-753.
               Cancer. 2018;65(5):e26946.                         doi: 10.1038/s41416-020-01180-1
               doi: 10.1002/pbc.26946                          83.  Piha-Paul SA, Hann CL, French CA,  et al. Phase 1 study
            74.  Leeman R, Pinkney K, Bradley JA, et al. NUT carcinoma   of molibresib (GSK525762), a bromodomain and extra-
               without upfront surgical resection: A case report. J Pediatr   terminal domain protein inhibitor, in NUT carcinoma and
               Hematol Oncol. 2021;43(5):e707-e710.               other solid tumors. JNCI Cancer Spectr. 2020;4(2):pkz93.
               doi: 10.1097/MPH.0000000000001865                  doi: 10.1093/jncics/pkz093
            75.  Lee JK, Louzada S, An Y,  et al. Complex chromosomal   84.  Lewin J, Soria JC, Stathis A,  et al. Phase Ib trial with
               rearrangements by single catastrophic pathogenesis in NUT   birabresib, a small-molecule inhibitor of bromodomain and
               midline carcinoma. Ann Oncol. 2017;28(4):890-897.  extraterminal proteins, in patients with selected advanced
                                                                  solid tumors. J Clin Oncol. 2018;36(30):3007-3014.
               doi: 10.1093/annonc/mdw686
                                                                  doi: 10.1200/JCO.2018.78.2292
            76.  Davis A, Mahar A, Wong K, Barnet M, Kao S. Prolonged
               disease control on nivolumab for primary pulmonary NUT   85.  Baneckova M, Cox D. Top 10 basaloid neoplasms of the
               carcinoma. Clin Lung Cancer. 2021;22(5):e665-e667.  sinonasal tract. Head Neck Pathol. 2023;17(1):16-32.
                                                                  doi: 10.1007/s12105-022-01508-8
               doi: 10.1016/j.cllc.2020.10.016
                                                               86.  French  CA.  Small-molecule  targeting  of  BET  proteins  in
            77.  Li X, Shi H, Zhang W, et al. Immunotherapy and targeting   cancer. Adv Cancer Res. 2016;131:21-58.
               the tumor microenvironment: Current place and new
               insights in  primary  pulmonary NUT  carcinoma.  Front      doi: 10.1016/bs.acr.2016.04.001
               Oncol. 2021;11:690115.                          87.  Reguerre Y, Lacour B, Andre N,  et al. Epidemiology
               doi: 10.3389/fonc.2021.690115                      and management of rare paediatric tumours within the
                                                                  framework of the French Society for Children Cancer. Bull
            78.  Kloker LD, Calukovic B, Benzler K,  et al. Case report:   Cancer. 2010;97(9):1041-1045.
               Immunovirotherapy as a novel add-on treatment in a patient
               with thoracic NUT carcinoma. Front Oncol. 2022;12:995744.     doi: 10.1684/bdc.2010.1169
               doi: 10.3389/fonc.2022.995744                   88.  Bisogno G, Ferrari A, Bien E,  et al. Rare cancers in
                                                                  children  -  The  EXPeRT  initiative: A  report  from  the
            79.  Wang  H,  Weiss  VL, Hoffman RD,  et al.  Salivary  gland   European cooperative study group on pediatric rare tumors.
               NUT carcinoma with prolonged survival in children: Case   Klin Padiatr. 2012;224(6):416-420.
               illustration and systematic review of literature. Head Neck
               Pathol. 2021;15(1):236-243.                        doi: 10.1055/s-0032-1327608
                                                               89.  Xin L, Zhuomiao Y. Expert consensus on the diagnosis and
               doi: 10.1007/s12105-020-01141-3
                                                                  treatment of midline (NUT) cancer (2023 Edition). Chin J
            80.  Esteves G, Ferreira J, Afonso R, Martins C, Zagalo C, Félix  A.   Oncol Prev Treat. 2023;15(5):463-476.
               HDAC overexpression in a NUT midline carcinoma of the   90.  United Nations Statistics Division. Population and Vital Statistics
               parotid gland with exceptional survival: A case report. Head   Report. United Nations Statistics Division; 2024. Available from:
               Neck Pathol. 2020;14(4):1117-1122.
                                                                  https://unstats.un.org/unsd/demographic-social/products/
               doi: 10.1007/s12105-020-01130-6                    vitstats/[EB/OL] [Last accessed on 2024 Apr 15].











            Volume 3 Issue 4 (2024)                         27                                doi: 10.36922/td.4904
   30   31   32   33   34   35   36   37   38   39   40